Avacta Group plc (AVCT) Ordinary Shares 10p
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
- Add to watchlist
- Create an alert
- This stock can be held in a
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
Avacta Group plc Ordinary Shares 10p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Update Pending
Share news, reports & tips
-
Avacta reaches milestone in AVA6000 dose escalation
21 March 2024 13:10
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
-
Avacta tumbles after raising £25.7m in heavily discounted placing
29 February 2024 08:27
(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
-
Avacta appoints new head of research and development
19 January 2024 11:18
(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.
-
Avacta appoints new chief business officer
19 December 2023 10:24
(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.
-
Avacta hails "encouraging" clinical data from cancer-targeting study
13 December 2023 07:46
(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".
-
Avacta reports higher losses in first half
28 September 2023 07:57
(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.
-
Avacta brings in clinical consultant as it hunts for permanent CMO
20 September 2023 11:57
(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.
-
Avacta upbeat on fresh data from chemotherapy trial
19 September 2023 13:39
(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and...
-
Avacta completes fifth dose escalation in chemotherapy trial
21 June 2023 13:53
(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.
-
Avacta denies press speculation over potential fundraising
19 June 2023 10:16
(Sharecast News) - Oncology drug developer Avacta Group responded to recent market speculation over a potential fundraising initiative on Monday.
-
Avacta triggers second milestone payment in AffyXell venture
5 June 2023 12:28
(Sharecast News) - Life science company Avacta Group announced on Monday that a second milestone equity payment had been triggered, resulting in an increased shareholding for Avacta in AffyXell Therapeutics.
-
Avacta buys Belgium-based Coris Bioconcept for £7.4m
1 June 2023 14:53
(Sharecast News) - Life science company Avacta Group announced the acquisition of Coris Bioconcept for initial cash consideration of £7.4m on Thursday.
Company announcements Announcements
-
Block listing Interim Return REPLACEMENT
26 April 2024 09:51
Avacta Group
-
Block Listing Six Monthly Return
26 April 2024 07:00
Avacta Group
-
Block Listing Application to AIM
23 April 2024 09:43
Avacta Group
-
Notice of Results
23 April 2024 07:00
Avacta Group
-
Issue of Equity and Total Voting Rights
22 April 2024 12:14
Avacta Group
-
Avacta Reports Data at the AACR Annual Meeting
9 April 2024 17:00
Avacta Group
-
AVA6000 Abstract Release by AACR
8 April 2024 07:00
Avacta Group
-
Update on AVA6000 Phase 1a Clinical Trial Progress
21 March 2024 07:00
Avacta Group
-
Result of General Meeting
18 March 2024 13:26
Avacta Group
-
Avacta Announces AVA6000 Poster at AACR
6 March 2024 07:00
Avacta Group
-
Result of REX Retail Offer
5 March 2024 07:00
Avacta Group
-
Result of Placing
29 February 2024 07:00
Avacta Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.